赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300485 赛升药业

已收盘 10-31 15:00:00

{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":12.46,"timestamp":1761894216000,"preClose":11.67,"halted":0,"volume":26204600,"delay":0,"changeRate":0.0677,"floatShares":274000000,"shares":482000000,"eps":0.1686,"marketStatus":"已收盘","change":0.79,"latestTime":"10-31 15:00:00","open":11.66,"high":12.48,"low":11.66,"amount":320000000,"amplitude":0.0703,"askPrice":12.46,"askSize":69,"bidPrice":12.45,"bidSize":122,"shortable":0,"etf":0,"ttmEps":0.1686,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":5,"adr":0,"adjPreClose":11.67,"symbolType":"stock","openAndCloseTimeList":[[1761874200000,1761881400000],[1761886800000,1761894000000]],"highLimit":12.84,"lowLimit":10.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.65,"roa":"--","peRate":73.902728,"roe":"1.53%","epsLYR":-0.14,"committee":-0.595633,"marketValue":6002000000,"turnoverRate":0.0957,"status":0,"floatMarketCap":3412000000},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2579597197","title":"赛升药业：截至2025年10月20日股东户数为37145","url":"https://stock-news.laohu8.com/highlight/detail?id=2579597197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579597197?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:57","pubTimestamp":1761814627,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止10月20号，公司的股东人数是多少？谢谢赛升药业回复：您好，截至2025年10月20日，公司股东户数为37145。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000030854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0046","300485","BK0239"],"gpt_icon":0},{"id":"2578712525","title":"赛升药业（300485）2025年三季报简析：净利润同比增长152.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578712525","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578712525?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:09","pubTimestamp":1761343761,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期赛升药业发布2025年三季报。根据财报显示，赛升药业净利润同比增长152.81%。截至本报告期末，公司营业总收入3.09亿元，同比下降4.41%，归母净利润5185.96万元，同比上升152.81%。按单季度数据看，第三季度营业总收入1.12亿元，同比上升3.5%，第三季度归母净利润407.33万元，同比下降41.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2577046203","title":"赛升药业最新公告：第三季度净利润同比下降41.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577046203","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577046203?lang=zh_cn&edition=full","pubTime":"2025-10-23 20:30","pubTimestamp":1761222607,"startTime":"0","endTime":"0","summary":"赛升药业(300485.SZ)公告称，赛升药业发布2025年第三季度报告，报告显示，公司前三季度实现营业收入3.09亿元，同比下降4.41%，但净利润达到5185.96万元，同比增长152.81%。第三季度单季，公司营业收入为1.12亿元，同比增长3.5%，净利润为407.33万元，同比下降41.41%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300035157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2575479931","title":"赛升药业(300485)9月30日股东户数3.34万户，较上期减少1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575479931","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575479931?lang=zh_cn&edition=full","pubTime":"2025-10-13 17:10","pubTimestamp":1760346639,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2025年9月30日公司股东户数为3.34万户，较9月19日减少618.0户，减幅为1.82%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.41万户。从股价来看，2025年9月19日至2025年9月30日，赛升药业区间跌幅为5.38%，在此期间股东户数减少618.0户，减幅为1.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300019341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0046","BK0028","BK0012","BK0239"],"gpt_icon":0},{"id":"2570098613","title":"赛升药业(300485)9月19日股东户数3.4万户，较上期减少0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570098613","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570098613?lang=zh_cn&edition=full","pubTime":"2025-09-25 17:33","pubTimestamp":1758792795,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2025年9月19日公司股东户数为3.4万户，较9月10日减少270.0户，减幅为0.79%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至9月19日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年9月10日至2025年9月19日，赛升药业区间跌幅为2.19%，在此期间股东户数减少270.0户，减幅为0.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500025666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","300485","BK0046","BK0028"],"gpt_icon":0},{"id":"2569205622","title":"股市必读：赛升药业（300485）9月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2569205622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569205622?lang=zh_cn&edition=full","pubTime":"2025-09-22 02:59","pubTimestamp":1758481148,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，赛升药业报收于12.08元，下跌0.74%，换手率3.22%，成交量8.81万手，成交额1.06亿元。董秘最新回复投资者： 请问董秘，贵司在研技术和产品，以往都有介绍。当日关注点来自交易信息汇总：9月19日主力资金净流出682.87万元，散户资金净流入1277.87万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200000979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0046","300485","BK0028"],"gpt_icon":0},{"id":"2568502572","title":"赛升药业(300485.SZ)股东马丽和刘淑芹拟合计减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2568502572","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568502572?lang=zh_cn&edition=full","pubTime":"2025-09-19 19:54","pubTimestamp":1758282870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司股东马丽女士和刘淑芹女士计划在2025年10月21日至2026年1月20日通过集中竞价和大宗交易方式减持公司股份数量合计不超过963.33万股，即不超过公司当前总股本的2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0239","BK0012","BK0028","300485"],"gpt_icon":0},{"id":"2568258490","title":"赛升药业：布局生命科学大健康产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2568258490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568258490?lang=zh_cn&edition=full","pubTime":"2025-09-19 15:39","pubTimestamp":1758267546,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)09月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，贵司在研技术和产品，以往都有介绍。贵司还涉猎生命科学大健康产业，请问有哪些产品或研究成果？赛升药业回复：您好，公司致力于生命科学技术产业化发展，通过自主创新，上、下游产业链整合，资本市场运作等方式布局覆盖生命科学大健康产业相关领域，以往介绍的产品、在研项目等均属于该范畴。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900019158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300485","BK0028","BK0012","BK0239"],"gpt_icon":0},{"id":"2568439896","title":"股市必读：赛升药业(300485)股东户数3.43万户，较上期减少1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568439896","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568439896?lang=zh_cn&edition=full","pubTime":"2025-09-17 05:30","pubTimestamp":1758058238,"startTime":"0","endTime":"0","summary":"截至2025年9月16日收盘，赛升药业报收于12.55元，上涨0.32%，换手率2.09%，成交量5.72万手，成交额7140.36万元。当日关注点来自交易信息汇总：9月16日主力资金净流出193.85万元，散户资金净流入658.75万元。股本股东变化股东户数变动近日赛升药业披露，截至2025年9月10日公司股东户数为3.43万户，较8月29日减少371.0户，减幅为1.07%。户均持股数量由上期的1.39万股增加至1.41万股，户均持股市值为17.36万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700006195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0046","300485","BK0028"],"gpt_icon":0},{"id":"2564380305","title":"股市必读：赛升药业（300485）9月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2564380305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564380305?lang=zh_cn&edition=full","pubTime":"2025-09-03 03:38","pubTimestamp":1756841895,"startTime":"0","endTime":"0","summary":"截至2025年9月2日收盘，赛升药业报收于13.75元，上涨2.0%，换手率7.68%，成交量21.03万手，成交额2.91亿元。当日关注点来自交易信息汇总：9月2日主力资金净流入1933.08万元，显示主力对赛升药业的积极介入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300003006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","300485","BK0046","BK0028"],"gpt_icon":0},{"id":"2564874834","title":"赛升药业：药品研发周期长、风险高，易受技术、审批、政策等影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2564874834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564874834?lang=zh_cn&edition=full","pubTime":"2025-09-02 15:45","pubTimestamp":1756799117,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)09月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董事长请问:公司的营业收入和利润连续几年下降，新药研发进展缓慢，为什么公司董事会和管理层却还把精力放在主业之外身兼数职搞投资副业？赛升药业回复：您好，因新药研发特性所致，药品研发需经多期临床，周期长、风险高，易受技术、审批、政策等影响。公司植根于医药产业，致力于生命科学技术产业化发展，通过自主创新，上、下游产业链整合，资本市场运作等方式布局覆盖生命科学大健康产业相关领域。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200021843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0046","300485","BK0028"],"gpt_icon":0},{"id":"2561401989","title":"赛升药业股价微涨0.49% 中报净利润4778万元实现扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2561401989","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561401989?lang=zh_cn&edition=full","pubTime":"2025-08-23 01:01","pubTimestamp":1755882061,"startTime":"0","endTime":"0","summary":"赛升药业最新股价为14.26元，较前一交易日上涨0.49%。盘中最高触及14.34元，最低下探至14.17元，成交量为120780手，成交金额达1.72亿元。2025年中报显示，公司实现营业总收入1.97亿元，归母净利润4778.62万元，较去年同期实现扭亏为盈。根据最新披露，赛升药业2025年中报显示经营活动现金净流入2934.19万元。资金流向方面，赛升药业当日主力资金净流出1398.33万元，近五日累计净流出5127.65万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/23010152635899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300485"],"gpt_icon":0},{"id":"2561142926","title":"赛升药业：截至2025年8月8日股东户数为38969","url":"https://stock-news.laohu8.com/highlight/detail?id=2561142926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561142926?lang=zh_cn&edition=full","pubTime":"2025-08-22 15:42","pubTimestamp":1755848539,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截止8月10号公司股东数是多少？赛升药业回复：您好，截至2025年8月8日，公司股东户数为38969。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200023724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","300485","BK0028","BK0239"],"gpt_icon":0},{"id":"2561492540","title":"赛升药业股价下跌1.80% 半年度净利润同比增长145.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561492540","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561492540?lang=zh_cn&edition=full","pubTime":"2025-08-21 23:58","pubTimestamp":1755791930,"startTime":"0","endTime":"0","summary":"赛升药业股价报14.19元，较前一交易日下跌0.26元，跌幅1.80%。赛升药业属于生物医药行业，主要从事生物生化药品的研发、生产和销售。2025年半年度报告显示，公司实现营业收入1.97亿元，同比下降8.40%；归属于上市公司股东的净利润4778.62万元，同比增长145.45%。研发投入2733.16万元，同比增长10.08%。公司计划于9月8日召开临时股东大会审议相关议案。8月21日主力资金净流出2886.31万元，近五日主力资金累计净流出6840.56万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/21235852598548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300485"],"gpt_icon":0},{"id":"2561746310","title":"图解赛升药业中报：第二季度单季净利润同比下降90.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561746310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561746310?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:34","pubTimestamp":1755768866,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业2025年中报显示，公司主营收入1.97亿元，同比下降8.4%；归母净利润4778.62万元，同比上升145.45%；扣非净利润864.36万元，同比下降52.21%；其中2025年第二季度，公司单季度主营收入1.04亿元，同比下降0.98%；单季度归母净利润781.62万元，同比下降90.85%；单季度扣非净利润745.36万元，同比上升154.34%；负债率4.65%，投资收益745.28万元，财务费用-7.91万元，毛利率64.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100029946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2559746670","title":"赛升药业：K11项目已进入Ⅲ期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2559746670","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559746670?lang=zh_cn&edition=full","pubTime":"2025-08-13 16:24","pubTimestamp":1755073449,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：据传贵公司K11适应症等III期临床试验目标组人数不足，请问是否如此？赛升药业回复：您好，K11项目已进入Ⅲ期临床试验阶段，启动了70余家研究中心进行试验，预计年底前完成全部入组，项目正常进行中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300025711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300485","BK0012","BK0046"],"gpt_icon":0},{"id":"2558836648","title":"赛升药业：赛典®单唾液酸四己糖神经节苷脂钠注射液适应症为用于急性缺血性脑卒中患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2558836648","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558836648?lang=zh_cn&edition=full","pubTime":"2025-08-12 17:03","pubTimestamp":1754989387,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司研发的长效GM1注射液目标适应症是帕金森病吗？药品生物利用度提升是否有所提升？该药品是否是国内独家？赛升药业回复：您好，公司产品赛典单唾液酸四己糖神经节苷脂钠注射液（GM-1/GM1）适应症为用于急性缺血性脑卒中患者。该产品为非国内独家产品。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081200028509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","300485","BK0046","BK0028"],"gpt_icon":0},{"id":"2557513286","title":"肝素概念盘中跳水，赛升药业跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557513286","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557513286?lang=zh_cn&edition=full","pubTime":"2025-08-08 09:43","pubTimestamp":1754617381,"startTime":"0","endTime":"0","summary":"08月08日，肝素概念盘中跳水，截至09点42分，肝素概念整体指数下跌0.51%，报1126.910点。从个股上来看，该概念的成分股中，赛升药业跌0.69%，华润双鹤、复星医药、健友股份跌幅居前。从资金上来看，截止发稿，肝素概念主力净流入为-3910.80万，其中千红制药受到资金热捧，主力净流入589.28万；拉长时间线来看，该板块近20日主力资金净流入-32.47亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808094301973ac2bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808094301973ac2bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0028","BK0046","300485","BK0186","603707","BK0012"],"gpt_icon":0},{"id":"2557659605","title":"赛升药业：公司持有绿竹生物股份及投资收益影响说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2557659605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557659605?lang=zh_cn&edition=full","pubTime":"2025-08-07 20:52","pubTimestamp":1754571147,"startTime":"0","endTime":"0","summary":"赛升药业回复：您好，目前公司直接持有绿竹生物13,751,500股，公司持股的生物医药并购一期基金持有绿竹生物19,645,000股，公司持股的生物医药并购二期基金持有绿竹生物18,324,696股，绿竹生物相关产品若成功上市，作为其股东，公司有望依托其业绩增长获得相应投资收益，同时，鉴于相关过程中存在不确定性，也可能会对投资收益产生影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700036455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300485","BK0185","BK0012","BK0188","BK0239","BK0196","600201","BK0077","BK0046"],"gpt_icon":0},{"id":"2557371537","title":"赛升药业：截至2025年7月31日股东户数为41761","url":"https://stock-news.laohu8.com/highlight/detail?id=2557371537","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557371537?lang=zh_cn&edition=full","pubTime":"2025-08-07 16:00","pubTimestamp":1754553658,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，你好!请问截止至2025年7月31日，公司股东人数总数是多少?谢谢!赛升药业回复：您好，截至2025年7月31日，公司股东户数为41761。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700024608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0239","BK0028","300485"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1761926077801,"stockEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":0.021},{"period":"3month","weight":-0.2093},{"period":"6month","weight":0.439},{"period":"1year","weight":0.481},{"period":"ytd","weight":0.6648}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.1199},{"period":"6month","weight":0.2159},{"period":"1year","weight":0.2206},{"period":"ytd","weight":0.1895}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37145人(较上一季度增加11.30%)","perCapita":"7371股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":"　　北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药。赛盈®纤溶酶注射液被评选为2023年年度生化生物企业优秀品牌，赛典®单唾液酸四己糖神经节苷脂钠注射液被评为2024年度生化、生物药品优秀品牌。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}